EXCLUSIVE: Soligenix Tells Benzinga HyBryte Expanded Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. -2.85%

Soligenix, Inc.

SNGX

2.39

-2.85%

EXCLUSIVE: Soligenix Tells Benzinga HyBryte Expanded Treatment Continues To Demonstrate Outcomes In -Early-Stage Cutaneous T-Cell Lymphoma
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via